We have extensive experience in modelling across a wide range of indications – our model experience includes budget impact models, cost effectiveness models, scenario models, cost calculator models, value-based pricing models, cost offset models, and cost utility models. Our experience is vast in this area and models have been developed for a large number of countries and with adaptations for different markets. We have developed models and model adaptations throughout Europe (including the EU5, eastern Europe and Scandinavia), on a Global scale, and for the US, Canada, Japan, Australia, Mexico and Brazil.
- Acromegaly
- Acute bacterial skin and skin structure infections (ABSSSI)
- Allergies
- Alzheimer’s disease
- Anaemia
- Anaesthesiology
- Ankylosing spondylitis
- Asthma
- Benign prostatic hyperplasia
- Bladder cancer
- Breakthrough cancer pain
- Breast cancer
- Cardiometabolic risk
- Chronic obstructive pulmonary disease (COPD)
- Clostridium difficile infections
- Colonoscopy
- Colorectal cancer
- Crohn’s disease
- Dengue fever
- Diabetes (type 1 and 2)
- Diabetic macular edema
- Dyslipidaemia
- Epilepsy
- Esophogeal cancer
- Gastric cancer
- Head and neck cancer
- Hepatitis C
- Hepatocellular carcinoma
- HIV
- Hormone replacement therapy
- HPV
- Human cord graft
- Hypertension
- Infection prevention
- Infertility
- Inflammatory bowel disease
- Influenza
- Leukaemia
- Lung cancer (small cell and non-small cell)
- Lymphomas
- Melanoma
- Mesothelioma
- Multiple myeloma
- Neuroendocrine tumours
- Neuromuscular block
- Osteoarthritis
- Ovarian cancer
- Pain
- Parkinson’s disease
- Phenylketonuria
- Pneumococcal disease
- Post-herpetic neuralgia
- Psoriasis
- Psoriatic arthritis
- Renal cell carcinoma
- Rheumatoid arthritis
- Surgery and post-operative pain
- Urothelial cancer